This post was originally published on this site
(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) has closed its investigation on Abbott Laboratories (NYSE:ABT)’ infant formula, with no additional cases of infections, according to a notice on the U.S. Food and Drug Administration website.
The agencies were investigating bacterial infections caused by the infant formula manufactured at Abbott’s Sturgis facility in Michigan.
